These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37748562)

  • 1. Risk factors in antiphospholipid antibody-associated valvular heart disease: A 383-patient cohort study.
    Pan H; Ding Z; Yang Z; Tang Z; Li L; Teng J; Sun Y; Liu H; Cheng X; Su Y; Ye J; Hu Q; Chi H; Zhou Z; Meng J; Ouyang B; Zhu Y; Yao H; Li J; Liu T; Yang C; Shi H
    Clin Immunol; 2023 Nov; 256():109790. PubMed ID: 37748562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between systemic lupus erythematosus and valvular heart disease: an extensive data analysis.
    Watad A; Tiosano S; Grysman N; Comaneshter D; Cohen AD; Shoenfeld Y; Amital H
    Eur J Clin Invest; 2017 May; 47(5):366-371. PubMed ID: 28295225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients.
    Li C; Zuo Y; Zhang S; Makris UE; Karp DR; Li Z
    Chin Med J (Engl); 2022 Mar; 135(6):658-664. PubMed ID: 35143425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study.
    Tonello M; Mattia E; Del Ross T; Favaro M; Calligaro A; Hoxha A; Bison E; Pengo V; Ruffatti A
    Clin Chim Acta; 2018 Oct; 485():74-78. PubMed ID: 29953850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study.
    Kampolis C; Tektonidou M; Moyssakis I; Tzelepis GE; Moutsopoulos H; Vlachoyiannopoulos PG
    Semin Arthritis Rheum; 2014 Feb; 43(4):558-65. PubMed ID: 24012042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus.
    Vivero F; Gonzalez-Echavarri C; Ruiz-Estevez B; Maderuelo I; Ruiz-Irastorza G
    Autoimmun Rev; 2016 Dec; 15(12):1134-1140. PubMed ID: 27639157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers.
    Tonello M; Mattia E; Favaro M; Del Ross T; Calligaro A; Salvan E; Hoxha A; Fedrigo M; Ruffatti A
    Thromb Res; 2019 May; 177():157-160. PubMed ID: 30903876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.
    de Jesús GR; Sciascia S; Andrade D; Barbhaiya M; Tektonidou M; Banzato A; Pengo V; Ji L; Meroni PL; Ugarte A; Cohen H; Branch DW; Andreoli L; Belmont HM; Fortin PR; Petri M; Rodriguez E; Cervera R; Knight JS; Atsumi T; Willis R; Nascimento IS; Rosa R; Erkan D; Levy RA;
    BJOG; 2019 Apr; 126(5):656-661. PubMed ID: 30222236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome.
    Kopytek M; Natorska J; Undas A
    Lupus; 2018 Apr; 27(5):812-819. PubMed ID: 29338587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.
    Žigon P; Podovšovnik A; Ambrožič A; Tomšič M; Hočevar A; Gašperšič N; Rotar Ž; Praprotnik S; Šemrl SS; Čučnik S
    Clin Rheumatol; 2019 Feb; 38(2):371-378. PubMed ID: 30099654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.
    Djokovic A; Stojanovich L; Stanisavljevic N; Djokic S; Filipovic B; Matic P; Milanovic M; Apostolovic S; Saponjski J
    Clin Rheumatol; 2022 May; 41(5):1447-1455. PubMed ID: 35018582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome.
    Djokovic A; Stojanovich L; Kontic M; Stanisavljevic N; Radovanovic S; Marisavljevic D
    Isr Med Assoc J; 2014 Mar; 16(3):162-7. PubMed ID: 24761704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-β
    Nakamura H; Oku K; Amengual O; Ohmura K; Fujieda Y; Kato M; Bohgaki T; Yasuda S; Atsumi T
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):627-634. PubMed ID: 28686816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valvular heart disease in antiphospholipid syndrome.
    Zuily S; Huttin O; Mohamed S; Marie PY; Selton-Suty C; Wahl D
    Curr Rheumatol Rep; 2013 Apr; 15(4):320. PubMed ID: 23456852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.
    Chen J; Sun S; Yan Q; Bao C; Fu Q
    Clin Rheumatol; 2016 Feb; 35(2):333-40. PubMed ID: 26753544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-β2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome.
    Liu T; Gu J; Wan L; Hu Q; Teng J; Liu H; Cheng X; Ye J; Su Y; Sun Y; Chi H; Zhou Z; Jia J; Wang Z; Zhou J; Norman GL; Wang X; Yang C; Shi H
    Thromb Res; 2020 Jan; 185():142-149. PubMed ID: 31816554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
    Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
    Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.